A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India

Phase 4 Completed 5 enrolled Takeda

NaSingle-groupOpen-labelTreatment

Summary

The main aim of this study is to learn more about the safety profile of Elaprase in Indian children and adults with hunter syndrome. Participants will receive Elaprase once per week over a 3-hour period which can be reduced to 1 hour as determined by the study doctor. Participants will need to visit the clinic weekly during the duration of the study.

Timeline

Start: 2022-04-21
Primary completion: 2024-04-06
Completion: 2024-04-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	idursulfase	Protein / enzyme biologic	0.5 mg/kg	Intravenous

Indications

No indication recorded.